Establish new prostate-specific antigen (PSA) baseline at least 3 mth after starting treatment & monitor PSA periodically thereafter during therapy. Increased risk of high-grade prostate cancer development. Consider for other urological conditions that may cause similar symptoms prior to initiation of treatment. Should not be handled by pregnant women or women w/ childbearing potential. Men should not donate blood until at least 6 mth following last dose. Lactation is contraindicated.